Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical Officer Dr. Walker will continue advancing Novavax's R&D efforts with ...

Jan 20 (Reuters) - Novavax ‌said on Tuesday it signed a licensing ‌agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, ...

Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant ...

Vaccine maker Novavax inked a three-year supply deal to include its adjuvant in vaccine research backed by an arm of the Bill & Melinda Gates Foundation. As part of the accord, Novavax will provide ...

Novavax reached a deal with Sanofi recently which sent the stock soaring. The company now expects to generate up to $1.2 billion in revenue this year. However, its long-term future remains hazy, and ...

Novavax has brought together its coronavirus vaccine with its expertise in flu to create a candidate that would protect people from both flu and COVID for the season. This could be particularly ...

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Novavax is a biotechnology company specializing in the ...

Good morning, and welcome to Novavax' First Quarter 2024 Financial Results and Operational Highlights Conference Call. All lines will be in a listen-only mode. [Operator Instructions]. Please note ...

GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr.